These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 33219256)

  • 41. Icotinib alone or with bevacizumab as first-line therapy in Chinese patients with advanced nonsquamous non-small cell lung cancer and activating EGFR mutations: A retrospective study.
    Jiang Z; Zhang J; Sun H; Wang C; Zhang Y; Li Y; Pan Z
    Thorac Cancer; 2021 Sep; 12(17):2369-2374. PubMed ID: 34255422
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of icotinib versus traditional chemotherapy as first-line treatment for preventing brain metastasis from advanced lung adenocarcinoma in patients with epidermal growth factor receptor-sensitive mutation.
    Zhao X; Zhu G; Chen H; Yang P; Li F; Du N
    J Cancer Res Ther; 2016; 12(3):1127-1131. PubMed ID: 28054523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
    Kosaka T; Yatabe Y; Endoh H; Yoshida K; Hida T; Tsuboi M; Tada H; Kuwano H; Mitsudomi T
    Clin Cancer Res; 2006 Oct; 12(19):5764-9. PubMed ID: 17020982
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
    Qu J; Wang YN; Xu P; Xiang DX; Yang R; Wei W; Qu Q
    Oncotarget; 2017 May; 8(20):33961-33971. PubMed ID: 28430623
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
    Kondo M; Yokoyama T; Fukui T; Yoshioka H; Yokoi K; Nagasaka T; Imaizumi K; Kume H; Hasegawa Y; Shimokata K; Sekido Y
    Lung Cancer; 2005 Dec; 50(3):385-91. PubMed ID: 16140420
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
    Lynch TJ; Bell DW; Sordella R; Gurubhagavatula S; Okimoto RA; Brannigan BW; Harris PL; Haserlat SM; Supko JG; Haluska FG; Louis DN; Christiani DC; Settleman J; Haber DA
    N Engl J Med; 2004 May; 350(21):2129-39. PubMed ID: 15118073
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.
    Gautschi O; Stadelmann C; Aebersold-Keller F; König K; Büttner R; Heukamp LC; Betticher D; Baumann C; Buser K; Calderoni A; Casty A; DʼAddario G; Irlé C; Mamot C; Morant R; Trojan A; Pellicioli E; Jehle-Schwertfeger S; Aebi S; Diebold J
    Oncol Res Treat; 2015; 38(11):560-9. PubMed ID: 26599269
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
    Kimura H; Suminoe M; Kasahara K; Sone T; Araya T; Tamori S; Koizumi F; Nishio K; Miyamoto K; Fujimura M; Nakao S
    Br J Cancer; 2007 Sep; 97(6):778-84. PubMed ID: 17848912
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.
    Ji W; Choi CM; Rho JK; Jang SJ; Park YS; Chun SM; Kim WS; Lee JS; Kim SW; Lee DH; Lee JC
    BMC Cancer; 2013 Dec; 13():606. PubMed ID: 24369725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer.
    Hellyer JA; Stehr H; Das M; Padda SK; Ramchandran K; Neal JW; Diehn M; Wakelee HA
    Lung Cancer; 2019 Aug; 134():42-45. PubMed ID: 31319993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
    Rizvi NA; Rusch V; Pao W; Chaft JE; Ladanyi M; Miller VA; Krug LM; Azzoli CG; Bains M; Downey R; Flores R; Park B; Singh B; Zakowski M; Heelan RT; Shen R; Kris MG
    Clin Cancer Res; 2011 May; 17(10):3500-6. PubMed ID: 21558399
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
    Varella-Garcia M; Mitsudomi T; Yatabe Y; Kosaka T; Nakajima E; Xavier AC; Skokan M; Zeng C; Franklin WA; Bunn PA; Hirsch FR
    J Thorac Oncol; 2009 Mar; 4(3):318-25. PubMed ID: 19247083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
    Sasaki H; Endo K; Konishi A; Takada M; Kawahara M; Iuchi K; Matsumura A; Okumura M; Tanaka H; Kawaguchi T; Shimizu T; Takeuchi H; Yano M; Fukai I; Fujii Y
    Clin Cancer Res; 2005 Apr; 11(8):2924-9. PubMed ID: 15837743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
    Wu JY; Yang CH; Hsu YC; Yu CJ; Chang SH; Shih JY; Yang PC
    Clin Lung Cancer; 2010 Jul; 11(4):257-63. PubMed ID: 20630828
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
    Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
    Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Histoculture drug response assay for gefitinib in non-small-cell lung cancer.
    Yoshimasu T; Ohta F; Oura S; Tamaki T; Shimizu Y; Naito K; Kiyoi M; Hirai Y; Kawago M; Okamura Y
    Gen Thorac Cardiovasc Surg; 2009 Mar; 57(3):138-43. PubMed ID: 19280309
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
    Zhang XT; Li LY; Mu XL; Cui QC; Chang XY; Song W; Wang SL; Wang MZ; Zhong W; Zhang L
    Ann Oncol; 2005 Aug; 16(8):1334-42. PubMed ID: 15956035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.